Castleark Management’s Intellia Therapeutics NTLA Stock Holding History

Castleark Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-32,140	Closed	-$1.8M	–	308
2022 Q3	$1.8M	Buy	+32,140	New	+$1.99M	0.1%	160
2022 Q1	–	Sell	-42,075	Closed	-$4.97M	–	348
2021 Q4	$4.97M	Buy	42,075 +3,055	+8%	+$383K	0.18%	130
2021 Q3	$5.24M	Buy	+39,020	New	+$5.91M	0.2%	120

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Castleark Management's NTLA Position: Q4 2022 in Review

Castleark Management sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 32,140 shares — an estimated $1.8M sold.

Castleark Management first reported a position in NTLA in Q3 2021 and held it in 3 quarters. The position peaked at $5.24M in Q3 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

Castleark Management reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
Castleark Management sold 32,140 Intellia Therapeutics shares in Q4 2022, an estimated $1.8M.
Castleark Management first reported a position in Intellia Therapeutics in Q3 2021 and held it in 3 quarters.
Castleark Management's Intellia Therapeutics position peaked at $5.24M in Q3 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Castleark Management's 13F filing for Q4 2022, filed 10 Feb 2023.